This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC